Repertoire Immune Medicines Announces Strategic Collaboration with Bristol Myers Squibb to Develop Tolerizing Vaccines for Three Autoimmune Diseases

On April 29, Repertoire Immune Medicines, a biotechnology company that pioneered the discovery and development of programmable T-cell-targeting immunotherapies, announced a collaboration agreement with Bristol-Myers Squibb to develop "tolerance vaccines" for three autoimmune diseases. This collaboration aims to reset the immune system and develop effective, selective, and durable treatments for patients with autoimmune diseases. Under the terms of the agreement, Repertoire will receive a $65 million upfront payment and up to $1.8 billion in milestone payments tied to achieving development, regulatory, and commercial goals, as well as tiered royalties. (Intelligent Finance & Economics)Original Link